Physician profile
Blake S Rust
NPI 1689961344
$5,506.30
in general payments reported to CMS, 2019-2025
21 companies · $1,519 in 2025
The $1,519 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,122 · 2020: $269 · 2021: $484 · 2022: $848 · 2023: $512 · 2024: $751 · 2025: $1,519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,064 · Consulting Fee: $701 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,063.84 |
| Consulting Fee | $700.91 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,320.73 | 2019-2025 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $684.78 | 2024-2025 | Xdemvy |
| Allergan, INC. | $575.13 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $475.41 | 2019-2025 | Cequa |
| Abbvie INC. | $410.15 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Alcon Vision LLC | $392.94 | 2019-2025 | Dailies Total1, Tryptyr, Eysuvis |
| Novartis Pharmaceuticals Corporation | $328.66 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $311.25 | 2022-2025 | Miebo, Xiidra, Infuse |
| Shire North American Group INC | $205.55 | 2019 | |
| Kala Pharmaceuticals, INC. | $141.41 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $141.24 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $130.88 | 2021-2024 | Acthar |
| Coopervision INC. | $124.37 | 2019 | |
| Oyster Point Pharma, INC. | $63.54 | 2022-2023 | Tyrvaya |
| Harrow Eye, LLC | $45.96 | 2024 | Vevye |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $36.55 | 2020 | |
| Dompe US, INC. | $31.40 | 2024-2025 | Oxervate |
| Abb Con-Cise Optical Group LLC | $26.43 | 2019 | |
| Biotissue Holdings INC. | $23.98 | 2025 | |
| Horizon Therapeutics Plc | $19.86 | 2022 | |
| Aerie Pharmaceuticals, INC. | $16.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Rust listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.